News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
516,739 Results
Type
Article (11770)
Company Profile (146)
Press Release (504822)
Multimedia
Podcasts (15)
Webinars (7)
Section
Business (170771)
Career Advice (585)
Deals (26264)
Drug Delivery (19)
Drug Development (60792)
Employer Resources (20)
FDA (11146)
Job Trends (9538)
News (251996)
Policy (19675)
Tag
2025 Best Places to Work (1)
2026 Best Places to Work (2)
2027 BioCapital Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (8)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (2)
2027 Genetown Premier (1)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
40 Under 40 (2)
Academia (679)
Accelerated approval (45)
ADA (27)
Adcomms (4)
Allergies (131)
Alliances (34096)
ALS (153)
Alzheimer's disease (1138)
Antibody-drug conjugate (ADC) (388)
Approvals (12004)
Artificial intelligence (415)
ASCO (200)
Autoimmune disease (296)
Automation (39)
Bankruptcy (268)
Belgium (10)
Best Places to Work (7627)
BIO (40)
Biologics (60)
BIOSECURE Act (1)
Biosimilars (159)
BioSpace Insights (20)
Biotechnology (90)
Bispecific (33)
Bladder cancer (179)
Brain cancer (49)
Breast cancer (608)
Cancer (4745)
Cardiovascular disease (377)
Career advice (514)
Career pathing (50)
CAR-T (228)
CDC (3)
CDMO (51)
Celiac Disease (3)
Cell therapy (582)
Cervical cancer (38)
Clinical research (56457)
Collaboration (1446)
Commercialization (35)
Company closure (3)
Compensation (1663)
Complete response letters (43)
COVID-19 (965)
CRISPR (76)
C-suite (897)
Cystic fibrosis (97)
Data (7718)
Decentralized trials (1)
Denatured (6)
Depression (131)
Dermatology (126)
Diabetes (519)
Diagnostics (4399)
Digital health (44)
Diversity (3)
Diversity, equity & inclusion (8)
Drug discovery (193)
Drug pricing (16)
Drug shortages (9)
Duchenne muscular dystrophy (196)
Earnings (75564)
Editorial (9)
Employer branding (2)
Employer resources (26)
ESMO (295)
Events (92905)
Executive appointments (766)
Eye disease (8)
FDA (14468)
Fibrodysplasia Ossificans Progressiva (13)
Fragile X (2)
Friedreich's ataxia (21)
Frontotemporal dementia (25)
Funding (1127)
Gene editing (149)
Generative AI (21)
Gene therapy (384)
GLP-1 (584)
Government (1264)
Grass and pollen (3)
Guidances (310)
Healthcare (10233)
Hematology (130)
HIV (68)
Huntington's disease (36)
Idiopathic pulmonary fibrosis (8)
IgA nephropathy (114)
Immunology and inflammation (165)
Immuno-oncology (85)
Indications (222)
Infectious disease (1200)
Inflammatory bowel disease (177)
Inflation Reduction Act (4)
Influenza (93)
Intellectual property (282)
Interviews (92)
IPO (12654)
IRA (3)
Job creations (2077)
Job search strategy (423)
JPM (4)
Kidney cancer (25)
Kidney disease (113)
Labor market (115)
Layoffs (234)
Leadership (22)
Legal (5469)
Licensing (61)
Liver cancer (53)
Longevity (29)
Lung cancer (701)
Lung diease (14)
Lymphoma (340)
Machine learning (33)
Management (7)
Manufacturing (684)
Marketing (28)
MASH (160)
Medical affairs (3)
Medical device (9036)
Medtech (9243)
Mergers & acquisitions (14786)
Metabolic disorders (1135)
mRNA (89)
Multiple sclerosis (153)
Multispecific (4)
NASH (15)
Netherlands (11)
Neurodegenerative disease (293)
Neuropsychiatric disorders (59)
Neuroscience (2309)
Neurotech (2)
NextGen: Class of 2026 (3387)
Non-profit (1251)
Now hiring (81)
Obesity (437)
Opinion (42)
Ovarian cancer (209)
Pain (213)
Pancreatic cancer (267)
Parkinson's disease (253)
Partnered (13)
Patents (538)
Patient advocacy (3)
Patient recruitment (618)
Patient selection (63)
Peanut (50)
People (42784)
Peptides (22)
Pharmaceutical (30)
Pharmacy benefit managers (13)
Phase 1 (17417)
Phase 2 (24983)
Phase 3 (18065)
Pipeline (9768)
Policy (28)
Postmarket research (1974)
Preclinical (6982)
Press Release (34)
Prostate cancer (258)
Psychedelics (23)
Radiopharmaceuticals (218)
Rare diseases (747)
Real estate (3157)
Recruiting (11)
Regenerative medicine (17)
Regulatory (16951)
Reports (34)
Research institute (850)
Resumes & cover letters (80)
Rett syndrome (49)
RNA editing (13)
RSV (58)
Schizophrenia (150)
Series A (186)
Series B (141)
Service/supplier (5)
Sickle cell disease (81)
Special edition (9)
Spinal muscular atrophy (111)
Sponsored (7)
Startups (2142)
Stem cells (3)
Stomach cancer (3)
Substance use disorders (18)
Supply chain (63)
Switzerland (7)
Tariffs (5)
The Weekly (9)
Vaccines (399)
Venture capital (36)
Weight loss (245)
Wet AMD (5)
Women's health (111)
Worklife (19)
Date
Today (1)
Last 7 days (790)
Last 30 days (2249)
Last 365 days (20886)
2026 (18213)
2025 (20970)
2024 (24752)
2023 (28310)
2022 (36418)
2021 (39178)
2020 (35411)
2019 (25702)
2018 (19202)
2017 (20186)
2016 (19172)
2015 (25549)
2014 (22615)
2013 (18862)
2012 (20951)
2011 (21216)
2010 (20949)
Location
Africa (289)
Alabama (83)
Alaska (2)
Arizona (331)
Arkansas (12)
Asia (20920)
Australia (2642)
California (13843)
Canada (3511)
China (856)
Colorado (555)
Connecticut (491)
Delaware (322)
Europe (31269)
Florida (2037)
Georgia (433)
Hawaii (3)
Idaho (47)
Illinois (892)
India (78)
Indiana (486)
Iowa (22)
Japan (539)
Kansas (109)
Kentucky (39)
Louisiana (41)
Maine (27)
Maryland (1359)
Massachusetts (9107)
Michigan (332)
Minnesota (627)
Mississippi (6)
Missouri (86)
Montana (20)
Nebraska (13)
Nevada (137)
New Hampshire (62)
New Jersey (3388)
New Mexico (14)
New York (3232)
North Carolina (1467)
North Dakota (6)
Northern California (6968)
Ohio (327)
Oklahoma (16)
Oregon (22)
Pennsylvania (2549)
Puerto Rico (25)
Rhode Island (36)
South America (472)
South Carolina (87)
South Dakota (1)
Southern California (5800)
Tennessee (135)
Texas (2226)
United States (45066)
Utah (419)
Vermont (1)
Virginia (188)
Washington D.C. (46)
Washington State (1038)
West Virginia (2)
Wisconsin (85)
Wyoming (3)
516,739 Results for "anges mg inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Lilly’s Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison
September 29, 2026
·
22 min read
Press Releases
Lupin Launches Raltegravir Tablets, USP, 600 mg in the United States
November 3, 2026
·
2 min read
Press Releases
Alembic Therapeutics LLC Announces Availability of Clonidine Hydrochloride Tablets, 0.05mg
October 13, 2026
·
1 min read
Press Releases
American Regent, Inc. Issues Voluntary Nationwide Recall of Three Lots of Epinephrine Injection, USP 30 mg/30 mL (1 mg/mL) Due to the Presence of Particulate Matter and Lack of Assurance of Sterility
September 3, 2026
·
4 min read
Press Releases
Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States
August 4, 2026
·
3 min read
Press Releases
Lilly’s Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
September 29, 2026
·
21 min read
Press Releases
Vitruvias Therapeutics, Inc. Issues Nationwide Recall of One Lot of Thyroid Tablets, USP 30 mg Due to Potential Super Potency
August 23, 2026
·
2 min read
Press Releases
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
October 14, 2026
·
9 min read
Press Releases
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE
October 21, 2026
·
7 min read
Press Releases
Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength
August 25, 2026
·
4 min read
1 of 51,674
Next